Trial Profile
Multicenter Phase II/III Clinical Study of Lipoplatin plus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 25 Nov 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 24 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 07 Jun 2011 New trial record